The Current Ratio as of July 2024 (TTM) for Madrigal Pharmaceuticals, Inc. (MDGL) is 9.39

According to Madrigal Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.39. This represents a change of 86.40% compared to the average of 5.04 of the last 4 quarters.

Madrigal Pharmaceuticals, Inc. (MDGL) Historical Current Ratio (quarterly & annually)

How has MDGL Current Ratio performed in the past?

The mean historical Current Ratio of Madrigal Pharmaceuticals, Inc. over the last ten years is 12.78. The current 9.39 Current Ratio has changed 7.25% with respect to the historical average. Over the past ten years (40 quarters), MDGL's Current Ratio was at its highest in in the June 2018 quarter at 90.37. The Current Ratio was at its lowest in in the September 2022 quarter at 1.59.

Madrigal Pharmaceuticals, Inc. (MDGL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Madrigal Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Madrigal Pharmaceuticals, Inc. (MDGL) Average Current Ratio

How has MDGL Current Ratio performed in the past?

The current Current Ratio of Madrigal Pharmaceuticals, Inc. (MDGL) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Madrigal Pharmaceuticals, Inc. (MDGL) Current Ratio vs. Peers

How is MDGL’s Current Ratio compared to its peers?

Madrigal Pharmaceuticals, Inc.’s Current Ratio is greater than Intercept Pharmaceuticals, Inc. (4.22), greater than TG Therapeutics, Inc. (3.62), less than Terns Pharmaceuticals, Inc. (27.85), greater than Hepion Pharmaceuticals, Inc. (5.99), less than Viking Therapeutics, Inc. (37.69), greater than Sarepta Therapeutics, Inc. (4.05), greater than PTC Therapeutics, Inc. (2.03), less than Day One Biopharmaceuticals, Inc. (10.93), greater than X4 Pharmaceuticals, Inc. (3.71), less than Inozyme Pharma, Inc. (14.05), less than Acumen Pharmaceuticals, Inc. (30.20), greater than Mereo BioPharma Group plc (4.86), less than 89bio, Inc. (15.03), less than Pliant Therapeutics, Inc. (16.12), greater than Arcellx, Inc. (5.46), greater than Stoke Therapeutics, Inc. (5.42), less than Krystal Biotech, Inc. (12.66), greater than Iovance Biotherapeutics, Inc. (4.63),

Build a custom stock screener for Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Madrigal Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Madrigal Pharmaceuticals, Inc. (MDGL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Madrigal Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.